Small Cell Lung Cancer ( SCLC ) Clinical Trials

17 studies are recruiting for small cell lung cancer ( sclc ) in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

   This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an a…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Bioresearch Partner - Hialeah Hospital, Hialeah, Florida

   Locations

   245 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07472517 on ClinicalTrials.gov

3. A Study of Armored CAR T Cells in People With Cancer

   The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07783477 on ClinicalTrials.gov

4. A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

   This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University Medicine, St Louis, Missouri

   Locations

   6 in total

   Run by

   Moonlight Bio, Inc

   See if you can join NCT07488923 on ClinicalTrials.gov

5. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

   The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   84 in total

   Run by

   Pfizer

   See if you can join NCT03460977 on ClinicalTrials.gov

6. Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

   This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants m…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Highlands Oncology Group, Fayetteville, Arkansas

   Locations

   83 in total

   Run by

   Pfizer

   See if you can join NCT07226999 on ClinicalTrials.gov

7. Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

   This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   30 in total

   Run by

   Pfizer

   See if you can join NCT07476287 on ClinicalTrials.gov

8. Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

   The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combin…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Henry Ford Cancer- Detroit, Detroit, Michigan

   Run by

   Bindu R Potugari

   See if you can join NCT07339059 on ClinicalTrials.gov

9. A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

   This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

   Locations

   15 in total

   Run by

   Phanes Therapeutics

   See if you can join NCT05652686 on ClinicalTrials.gov

10. Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

    This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois Chicago, Chicago, Illinois

    Locations

    3 in total

    Run by

    Alliance Foundation Trials, LLC.

    See if you can join NCT07149363 on ClinicalTrials.gov

11. Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

    This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Run by

    Misty Shields

    See if you can join NCT07153055 on ClinicalTrials.gov

12. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Start Lacn, Los Angeles, California

    Locations

    3 in total

    Run by

    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT07517198 on ClinicalTrials.gov

13. Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory University Hospital, Atlanta, Georgia

    Locations

    5 in total

    Run by

    Molecular Partners AG

    See if you can join NCT07278479 on ClinicalTrials.gov

14. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dothan Hematology & Oncology, Dothan, Alabama

    Locations

    4 in total

    Run by

    Radiopharm Theranostics, Ltd

    See if you can join NCT07189871 on ClinicalTrials.gov

15. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    13 in total

    Run by

    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov

16. JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

    This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Health System, Detroit, Michigan

    Locations

    8 in total

    Run by

    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT05490472 on ClinicalTrials.gov

17. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Providence Medical Foundation (site 209), Santa Rosa, California

    Locations

    15 in total

    Run by

    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov